With the realization that the gross genetic abnormalities that activated MYC in cancer universally led to deregulated expression of the intact coding region, a series of new questions arose.

The findings have been published in Nature. The team found that some pancreatic cancer cells gain a major survival edge by carrying copies of critical cancer genes—such as MYC—on circular pieces of ...

The work demonstrates that initial MYC activation attracts immune cells to the tumor but later helps hide the tumor from immune cells. This discovery is the first step toward identifying potential ...

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

which cause therapeutic vulnerabilities in breast cancer. Our current research specifically focuses on therapeutic strategies aiming to exploit MYC oncogene-induced vulnerabilities and therapeutically ...

Neuroblastomas are the most common cancer in infants, with about 700–800 diagnoses per year in the US, according to the American Cancer Society. Some of the most high-risk cases are driven by elevated ...

Importantly, we also discovered that certain mutations, like MYC, appear early in prostate cancer development and are linked to more aggressive forms of the disease. If these mutations occur in ...

Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary ...

Dewpoint will present two posters at AACRCondensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of ...

A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...